Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein ...
Hyperlipidemia is a powerful and extremely common risk factor for cardiovascular disease (CVD) among all racial/ethnic groups. However, there are certain racial/ethnic differences in the ...
Bempedoic acid has a novel mechanism of action that inhibits a cholesterol synthesis pathway by acting on ATP (adenosine triphosphate) citrate lyase, a citrate-degrading enzyme in the liver. Bempedoic ...
Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.